Drugs / Fully human anti CD19 CAR-T Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04732845 | Apr 2021 → Sep 2025 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | Benjamin Tomlinson | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fully human anti CD19 CAR-T Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04732845 ↗ |
| Modality | Cell therapy | “specific type of cells that will be used is called human chimeric antigen receptor T cells (CAR-T cells)” NCT04732845 ↗ |
| Route | Intravenous | “returned to the body through an intravenous (IV) infusion” NCT04732845 ↗ |
| Target | CD19 | “chimeric antigen receptor T cells targeting CD19” NCT04732845 ↗ |